Clinical translation of the GRPR antagonist [99mTc]Tc-maSSS-PEG2-RM26 for targeting prostate tumors

被引：0
|
作者：
Orlova, Anna [1 ]
Abouzayed, Ayman [1 ]
Rinne, Sara [1 ]
Lushnikova, Nadezhda [2 ]
Usynin, Evgeny [2 ]
Doroshenko, A. [2 ]
Borin, Jesper [3 ]
Sorensen, Jens [1 ]
Tolmachev, Vladimir [1 ]
Chernov, Vladimir [2 ]
Rybina, Anastasia [2 ]
机构：
[1] Uppsala Univ, Uppsala, Sweden
[2] Russian Acad Sci, Tomsk Natl Res Med Ctr, Moscow, Russia
[3] KTH Royal Inst Technol, Stockholm, Sweden
来源：
NUCLEAR MEDICINE AND BIOLOGY | 2022年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P-54
引用
收藏
页码：S58 / S58
页数：1
相关论文
共 49 条
  • [41] Synthesis and evaluation of 99mTc-analogues of [123/131I]mIBG prepared via [99mTc][Tc(CO)3(H2O)3]+ synthon for targeting norepinephrine transporter
    Das, Soumen
    Sakhare, Navin
    Mathur, Anupam
    Mallia, Madhava B.
    Mirapurkar, Shubhangi
    Sheela, M.
    Sarma, H. D.
    Sachdev, S. S.
    Dash, Ashutosh
    NUCLEAR MEDICINE AND BIOLOGY, 2019, 68-69 : 49 - 57
  • [42] 99mTc targeting of Sst2-expressing tumors by tetraamine-octreotide:: First results in CA20948 cells and rat models
    Nikolopoulou, A
    Nock, BA
    Maina, T
    ANTICANCER RESEARCH, 2006, 26 (1A) : 363 - 366
  • [43] [99mTc]Tc-DGA1, a Promising CCK2R-Antagonist-Based Tracer for Tumor Diagnosis with Single-Photon Emission Computed Tomography
    Kaloudi, Aikaterini
    Kanellopoulos, Panagiotis
    Radolf, Thorsten
    Chepurny, Oleg G.
    Rouchota, Maritina
    Loudos, George
    Andreae, Fritz
    Holz, George G.
    Nock, Berthold Artur
    Maina, Theodosia
    MOLECULAR PHARMACEUTICS, 2020, 17 (08) : 3116 - 3128
  • [44] Synthesis and evaluation of [186Re]Re(CO)3-p-NCS-benzyl-NODAGA-Ser2-RM2 for future development as a GRPR-antagonist for targeting prostate cancer
    Hoerres, Rebecca
    Kankanamalage, Pavithra H. A.
    Gallazzi, Fabio
    Hennkens, Heather
    NUCLEAR MEDICINE AND BIOLOGY, 2021, 96-97 : S90 - S91
  • [45] Selection of the First 99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation-Preclinical Assessment of Two Optimized Candidates
    Fani, Melpomeni
    Weingaertner, Viktoria
    Kolenc Peitl, Petra
    Mansi, Rosalba
    Gaonkar, Raghuvir H.
    Garnuszek, Piotr
    Mikolajczak, Renata
    Novak, Doroteja
    Simoncic, Urban
    Hubalewska-Dydejczyk, Alicja
    Rangger, Christine
    Kaeopookum, Piriya
    Decristoforo, Clemens
    PHARMACEUTICALS, 2021, 14 (01) : 1 - 15
  • [46] An improved kit formulation for one-pot synthesis of [99mTc]Tc-HYNIC-E[c(RGDfK)]2 for routine clinical use in cancer imaging
    Chakraborty, Sudipta
    Das, Soumen
    Chakravarty, Rubel
    Sarma, Haladhar Dev
    Vatsa, Rakhee
    Shukla, Jaya
    Mittal, Bhagwant Rai
    Dash, Ashutosh
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 (12): : 823 - 834
  • [47] In-house production of [99mTc][Tc-HYNIC-TATE] cold kit for the diagnosis of neuroendocrine tumors in Pakistan: pre-clinical and clinical evaluation of indigenously manufactured single and dual vial kit formulation
    Rizvi, Shakera Khatoon
    Tariq, Saima
    Gilani, Farkhanda
    Javed, Amna
    Rafique, Iqra
    JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, 2025, 334 (01) : 141 - 152
  • [48] Radiation dosimetric and biodistribution comparison of the PSMA agonists 177Lu-PSMA I&T, 99mTc-Hynic PSMA and 99Tc-PSMA I&T to the 177Lu-RM2 antagonist
    Limouris, G.
    Paphiti, M.
    Zafeirakis, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S459 - S459
  • [49] Single-Photon Emission Computer Tomography Imaging of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Cancer Patients Using a Novel Peptide-Based Probe [99mTc]Tc-BQ0413 with Picomolar Affinity to PSMA: A Phase I/II Clinical Study
    Medvedeva, Anna
    Chernov, Vladimir
    Larkina, Maria
    Rybina, Anastasiya
    Zelchan, Roman
    Bragina, Olga
    Varvashenya, Ruslan
    Zebzeeva, Olga
    Bezverkhniaia, Ekaterina
    Tolmachev, Vladimir
    Orlova, Anna
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2025, 8 (03) : 736 - 747
12345